Equities analysts expect Celsion Co. (NASDAQ:CLSN) to post ($0.25) earnings per share for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for Celsion’s earnings, with the highest EPS estimate coming in at ($0.15) and the lowest estimate coming in at ($0.34). Celsion reported earnings of $0.32 per share during the same quarter last year, which suggests a negative year over year growth rate of 178.1%. The business is expected to report its next quarterly earnings report on Friday, April 3rd.
On average, analysts expect that Celsion will report full-year earnings of ($0.96) per share for the current year, with EPS estimates ranging from ($1.05) to ($0.82). For the next fiscal year, analysts forecast that the firm will post earnings of ($0.62) per share, with EPS estimates ranging from ($0.77) to ($0.54). Zacks’ EPS calculations are an average based on a survey of sell-side research analysts that follow Celsion.
Celsion (NASDAQ:CLSN) last announced its quarterly earnings data on Friday, November 15th. The biotechnology company reported ($0.25) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.05. Celsion had a negative return on equity of 57.46% and a negative net margin of 1,653.20%. The business had revenue of $0.13 million for the quarter, compared to analyst estimates of $0.13 million.
NASDAQ CLSN traded up $0.04 during trading hours on Friday, reaching $1.48. The stock had a trading volume of 17,795 shares, compared to its average volume of 229,145. The stock has a fifty day moving average of $1.50 and a 200 day moving average of $1.73. The stock has a market cap of $32.49 million, a P/E ratio of -2.18 and a beta of 1.87. Celsion has a 52-week low of $1.05 and a 52-week high of $2.63. The company has a debt-to-equity ratio of 0.67, a quick ratio of 2.58 and a current ratio of 2.58.
A hedge fund recently raised its stake in Celsion stock. BlackRock Inc. boosted its stake in shares of Celsion Co. (NASDAQ:CLSN) by 5.1% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 146,332 shares of the biotechnology company’s stock after acquiring an additional 7,070 shares during the quarter. BlackRock Inc. owned 0.71% of Celsion worth $267,000 at the end of the most recent reporting period. 5.95% of the stock is owned by hedge funds and other institutional investors.
Celsion Company Profile
Celsion Corporation, a development stage oncology drug company, focuses on the development and commercialization of directed chemotherapies, DNA-mediated immunotherapy, and RNA based therapies for the treatment of cancer. Its lead product candidate is ThermoDox, a liposomal encapsulation of doxorubicin that is in Phase III clinical trial for treating primary liver cancer.
Featured Story: Understanding Options Trading
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Celsion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celsion and related companies with MarketBeat.com's FREE daily email newsletter.